Adherence to Iron Chelation Therapy with Deferasirox Formulations among Patients with Sickle Cell Disease and β-thalassemia.
CONCLUSION: There was significant improvement in adherence to iron chelation therapy when patients transitioned from deferasirox DT to deferasirox FCT.
PMID: 32892996 [PubMed - as supplied by publisher]
Source: Journal of the National Medical Association - Category: General Medicine Tags: J Natl Med Assoc Source Type: research
More News: Cancer & Oncology | Children | General Medicine | Hematology | Iron | Sickle Cell Anemia | Study